Journal article
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial
Abstract
BACKGROUND: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban versus aspirin in patients with recent ESUS.
AIMS: We aimed to describe the baseline characteristics of this large ESUS cohort to explore relationships among key subgroups.
Authors
Kasner SE; Lavados P; Sharma M; Wang Y; Wang Y; Dávalos A; Shamalov N; Cunha L; Lindgren A; Mikulik R
Journal
Journal of Stroke and Cerebrovascular Diseases, Vol. 27, No. 6, pp. 1673–1682
Publisher
Elsevier
Publication Date
6 2018
DOI
10.1016/j.jstrokecerebrovasdis.2018.01.027
ISSN
1052-3057